CTI BioPharma (CTIC) : Zacks Investment Research ranks CTI BioPharma (CTIC) as 2, which is a Buy recommendation. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 3 research analysts is 3.67, which indicates as a Sell.
CTI BioPharma (CTIC) : The highest level CTI BioPharma (CTIC) is projected to reach is $5 for the short term and the lowest estimate is at $1. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $2.88 and the possibility the share price can swing is $3.01.
Company shares have received an average consensus rating of Hold for the current week
CTI BioPharma (NASDAQ:CTIC): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.38 and $0.37 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.39. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.38, notching a gain of 4.59% for the day. The total traded volume was 1,403,008 . The stock had closed at $0.36 on the previous day.
CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.